multiple sclerosis treatment

Multiple sclerosis research charges ahead with new mouse model of disease

harminka — Thu, 06 Nov 2008 06:28:02 -0600

A new study highlights the role of a charge-switching enzyme in nervous system deficits characteristic of multiple sclerosis and other related neurological illness.

Interferon could be key to preventing or treating multiple sclerosis

harminka — Thu, 30 Oct 2008 14:49:59 -0500

Multiple sclerosis (MS) results when the body's own defense system attacks nerve fibers in the brain and spinal cord. Now scientists led by John Russell, Ph.D., at Washington University School of Medicine in St. Louis have shown that interferon-gamma plays a deciding role in whether immune cells attack and injure the central nervous system (brain and spinal cord) in mice.

BG-12 significantly reduced brain lesions in multiple sclerosis

harminka — Fri, 24 Oct 2008 08:05:05 -0500

Biogen Idec (NASDAQ: BIIB) today announced the publication of Phase IIb data showing that a 240 mg three-times-daily dose of the company's novel oral compound, BG-12 (BG00012, dimethyl fumarate), reduced the number of new gadolinium enhancing (Gd+) lesions by 69 percent in patients with relapsing-remitting multiple sclerosis (MS) when compared to treatment with placebo (p<0.0001).

New hope for multiple sclerosis sufferers

harminka — Thu, 23 Oct 2008 10:06:27 -0500

esearch indicates drug not only stops the disease from advancing but may also restore lost function in many patients

Milestone for cannabinoid MS study

harminka — Mon, 21 Jul 2008 12:42:27 -0500

The CUPID (Cannabinoid Use in Progressive Inflammatory brain Disease) study at the Peninsula Medical School in Plymouth has reached an important milestone with the news that the full cohort of 493 people with multiple sclerosis (MS) has been recruited to the study.

Best treatment for MS may depend on disease subtype

harminka — Wed, 02 Jul 2008 09:48:02 -0500

Animal studies by University of Michigan scientists suggest that people who experience the same clinical signs of multiple sclerosis (MS) may have different forms of the disease that require different kinds of treatment.

Prozac may help to curb disease activity in multiple sclerosis

harminka — Thu, 01 May 2008 03:26:49 -0500

The antidepressant Prozac may help to curb disease activity in the relapsing remitting form of multiple sclerosis (MS), reveals preliminary research published ahead of print in the Journal of Neurology Neurosurgery and Psychiatry.

Eye test peers into heat-related multiple sclerosis symptoms

harminka — Fri, 21 Mar 2008 11:21:14 -0500

A bodysuit that heats or cools a patient, combined with painless measurements of eye movements, is providing multiple sclerosis researchers at UT Southwestern Medical Center with a new tool to study the mysterious link between body temperature and severity of MS symptoms.

Smoking marijuana impairs cognitive function in multiple sclerosis patients

harminka — Thu, 14 Feb 2008 08:01:57 -0600

People with multiple sclerosis (MS) who smoke marijuana are more likely to have emotional and memory problems, according to research published February 13, 2008, in the online edition of Neurology®, the medical journal of the American Academy of Neurology.

Experimental multiple sclerosis drug shows promise, offers new window on disease

harminka — Thu, 14 Feb 2008 07:58:21 -0600

A drug therapy currently used to treat non-Hodgkin’s lymphoma and rheumatoid arthritis had a significant effect in treating the most common form of multiple sclerosis in a small, short-term clinical trial.

New therapeutic target for treatment of multiple sclerosis

harminka — Tue, 22 Jan 2008 11:51:06 -0600

An international research team, led by a scientist from the Centre hospitalier de l’Université de Montréal (CHUM), has identified new therapeutic targets for the treatment of multiple sclerosis (MS).

Anti-inflammation molecule helps fight MS-like disease

harminka — Sun, 11 Nov 2007 14:20:51 -0600

An immune system messenger molecule that normally helps quiet inflammation could be an effective tool against multiple sclerosis (MS).